BLUE

CytoDyn Announces Preliminary Results from 2021 Annual Meeting

Wednesday, November 24, 2021 - 9:01pm

CytoDyn Inc. (OTCQB: CYDY) (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced the preliminary vote results from the 2021 Annual Meeting of Stockholders (the Annual Meeting), which was held today.

Key Points: 
  • CytoDyn Inc. (OTCQB: CYDY) (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced the preliminary vote results from the 2021 Annual Meeting of Stockholders (the Annual Meeting), which was held today.
  • The official results for each of these proposals will be disclosed in a report to be filed on Form 8-K with the Securities and Exchange Commission.
  • CytoDyn has filed with the SEC a definitive proxy statement and associated BLUE proxy card in connection with the solicitation of proxies for the Companys 2021 Annual Meeting.
  • Details concerning the nominees of the Companys Board of Directors for election at the 2021 Annual Meeting are included in the proxy statement.

Comtech Files New Investor Presentation

Wednesday, November 24, 2021 - 1:30pm

The presentation is available under the stockholder materials section of https://comtechcreates.com .

Key Points: 
  • The presentation is available under the stockholder materials section of https://comtechcreates.com .
  • The investor presentation highlights the transformative actions that Comtechs Board of Directors and management team have taken over the past five years to enhance the Companys leadership position in attractive growth markets and accelerate growth and profitability.
  • The presentation also outlines the actions the Board has taken to add new directors who bring a strong mix of skills, experience, diversity and fresh viewpoints for the benefit of Comtech shareholders.
  • Headquartered in Melville, New York and with a passion for customer success, Comtech designs, produces and markets advanced and secure wireless solutions.

Webtoon Production Company CONTENTS LAB. BLUE Secures KRW 10B in Series A Finance

Monday, November 22, 2021 - 9:00am

Seoul, Korea, Nov 22, 2021 - (ACN Newswire) - Webtoon production company CONTENTS LAB.

Key Points: 
  • Seoul, Korea, Nov 22, 2021 - (ACN Newswire) - Webtoon production company CONTENTS LAB.
  • With this funding round, the Company has secured total investment of KRW 13B (approx US$10.9M).
  • While strong production capability is resulting in record performance in overseas webtoon markets, CONTENTS LAB.
  • BLUE has also concluded multiple contracts to create drama series and movies based on their contents.

Comtech Urges Stockholders to Get to Know Its Outstanding Director Candidates

Monday, November 22, 2021 - 1:30pm

We say, we believe, because after only an initial introductory meeting, Outerbridge refused to allow us to vet these candidates following our standard process.

Key Points: 
  • We say, we believe, because after only an initial introductory meeting, Outerbridge refused to allow us to vet these candidates following our standard process.
  • A cursory review of Outerbridges proxy filing and other public information, however, reveals clear red flags:
    Wendi Carpenter is unqualified to serve as a director at Comtech.
  • Ms. Carpenter has been a public company director at only one company, newly public SkyWater Technology, for a total of seven months.
  • These director candidates reflect Outerbridges limited understanding of our business, our capital needs, our strategy, and our end markets.

NEC Takes On-premises Phone Systems to the Cloud With UNIVERGE BLUE® CONNECT BRIDGE

Wednesday, November 17, 2021 - 2:00pm

UNIVERGE BLUE CONNECT BRIDGE extends existing NEC phone systems with cloud-based voice via desktop and mobile apps creating a seamless all-in-one highly collaborative communications experience and unlocking new cloud-based applications.

Key Points: 
  • UNIVERGE BLUE CONNECT BRIDGE extends existing NEC phone systems with cloud-based voice via desktop and mobile apps creating a seamless all-in-one highly collaborative communications experience and unlocking new cloud-based applications.
  • UNIVERGE BLUE CONNECT BRIDGE enables NEC customers to keep their existing phone system and phone numbers, while adding the tools teams need to better communicate and collaborate.
  • The addition of UNIVERGE BLUE CONNECT BRIDGE is a significant expansion to NECs highly acclaimed UNIVERGE BLUE platform.
  • We have been very happy with the NECs UNIVERGE BLUE CONNECT BRIDGE and it works seamlessly with our NEC UNIVERGE SV9100 PBX.

Mazoola (SM) Teaches Kids About Gift Giving and Social Responsibility with A Safe, Smart and Easy to Use Family Digital Wallet

Friday, November 19, 2021 - 1:00pm

A common concern among parents during the holiday timeframe is how to help their children enjoy giving during a time when they are much more eager to receive.

Key Points: 
  • A common concern among parents during the holiday timeframe is how to help their children enjoy giving during a time when they are much more eager to receive.
  • Charitable contributions allow kids to gain valuable perspectives on those less fortunate than themselves, producing a more grateful and compassionate youth for the future.
  • "The winter holiday season is the perfect time to teach kids about generosity," said REGO Head of Strategy Dan Aptor.
  • Mazoola teaches kids the value of money, the cost of gifts, the responsibility of saving, and the experience of giving."

UBC Up for Clinical Research Team of the Year

Thursday, November 18, 2021 - 3:00pm

This data has ultimately contributed to more thoroughly understanding the efficacy and safety of novel therapies for SMA.

Key Points: 
  • This data has ultimately contributed to more thoroughly understanding the efficacy and safety of novel therapies for SMA.
  • The Gene Therapy Registry Team is a cross-functional team that has worked daily for over two years to propel the registry forward.
  • United BioSource LLC (UBC) is a leader in the biopharmaceutical market which provides integrated clinical, safety, and commercialization services.
  • UBC brings together renowned scientific research and operations experts with innovative technologies, allowing for the best patient and healthcare provider experience.

Unisys Acquires Unified Endpoint Management Expert Mobinergy™ to Expand its End-User Experience Solutions

Thursday, November 18, 2021 - 2:22pm

Unisys is funding the transaction with cash on handand will focus on growing Mobinergy activities globally to expand its UEM business.

Key Points: 
  • Unisys is funding the transaction with cash on handand will focus on growing Mobinergy activities globally to expand its UEM business.
  • "Unisys continues to acquire capabilities that enhance our core solutions and accelerate the innovation we deliver to clients,"said Leon Gilbert, senior vice president and general manager, Digital Workplace Solutions, Unisys.
  • "Mobinergy capabilities willenable Unisys to deliver high-value UEM solutions to our clients and further expand our employee experience portfolio."
  • Unisys offerings include digital workplace solutions, cloud and infrastructure solutions, enterprise computing solutions, business process solutions and cybersecurity solutions.

CytoDyn Reminds Stockholders to Register 24 hours before November 24th Annual Meeting

Tuesday, November 16, 2021 - 7:00pm

VANCOUVER, Washington, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today urged stockholders to register 24 hours prior to the meeting time in order to participate in this meeting. The upcoming 2021 Annual Meeting of Stockholders, as previously announced, was adjourned to now be held on November 24, 2021 (the “Annual Meeting”) at 8:00 a.m. Pacific Time.

Key Points: 
  • CytoDyn is working diligently to resubmit its BLA for this HIV combination therapy since receiving a Refusal to File in July 2020.
  • CytoDyn also completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.
  • CytoDyn has filed with the SEC a definitive proxy statement and associated BLUE proxy card in connection with the solicitation of proxies for the Companys 2021 Annual Meeting.
  • Details concerning the nominees of the Companys Board of Directors for election at the 2021 Annual Meeting are included in the proxy statement.

Protinhi Therapeutics selected as part of BLUE KNIGHT™ collaboration for pandemic preparedness

Tuesday, November 16, 2021 - 1:00pm

NIJMEGEN, The Netherlands, Nov. 16, 2021 /PRNewswire/ -- Protinhi Therapeutics, a Netherlands-based biotechnology company specializing in protease inhibition with the aim to combat viral infectious diseases, today announced it has been selected to join BLUE KNIGHT™, a global community of early-stage biotech companies.

Key Points: 
  • Blue Knightis a joint initiative created between Johnson & Johnson Innovation JLABS ('JLABS') and the Biomedical Advanced Research and Development Authority (BARDA).
  • Protinhi is the third European biotech startup to become a Blue Knight company, and its selection highlights the growth trajectory of a company operating in a priority area with high unmet medical need.
  • Operationally active since 2016, Protinhi specializes in the development of novel antivirals against upcoming viral health threats.
  • [ii]
    As a Blue Knight company, Protinhi can benefit from continuing support and assistance within the JLABS' global innovation ecosystem.